RIPK1 and atherosclerosis: Here, we report that GSK547 (RIPK1i), a mono-selective kinase inhibitor that robustly targets RIPK1 in vivo (19) plays a dual role in lipid metabolism and inflammation, conferring a stage-dependent impact on atherosclerosis.